Today
+3.03%
5 Days
+0.62%
1 Month
+8.62%
6 Months
+29.28%
Year to Date
+27.65%
1 Year
+52.17%
CVS Health Corp's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 44 out of 76 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 101.70.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Media Coverage
TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.

TradingKey - The healthcare system was one of the first industries to go through a major transformation; now, investors are watching closely. Every day, we see new technology being created for diagnosing and treating diseases. The method of delivery in allowing patients access to care has changed al

TradingKey - In the midst of a chaotic healthcare environment of price scrutiny, margin pressure, and shifting consumer behavior, CVS Health (CVS) has undertaken a conscious shift: less bulk, more acuity.



Related Instruments
Popular Instruments